SCHEMBL16201381

SCHEMBL16201381

CCCN(C)Cc1c[nH]nc1-c1ccccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 2/20 0.41
CARM1 Q86X55 2/20 0.36
PRMT3 O60678 1/20 0.36
PRMT6 Q96LA8 1/20 0.36
PRMT8 Q9NR22 1/20 0.36
HTR1A P08908 3/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
PYCR1 P32322 1/20 0.35
GPBAR1 Q8TDU6 1/20 0.35
HTR7 P34969 2/20 0.34
PRMT1 Q99873 1/20 0.34
LIMK1 P53667 1/20 0.34
DPP4 P27487 1/20 0.34
HSP90AA1 P07900 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201212 0.88 CARM1 (0.49) CARM1PRMT3PRMT6PRMT8PRMT1
SCHEMBL16201388 0.88 CFD (0.34) CRHR1CARM1PRMT3PRMT6PRMT8
SCHEMBL16201417 0.85 MEN1 (0.39) HTR7MEN1KMT2ATDP1KDM4E
SCHEMBL16201352 0.85 CRHR1 (0.43) CRHR1PYCR1CYP1A2CYP3A4CYP2D6
SCHEMBL16201351 0.84 LMNA (0.44) HTR1AHTR2CHTR7HSP90AA1MEN1
SCHEMBL16201377 0.84 CRHR1 (0.38) CRHR1KDM4E
SCHEMBL16201354 0.84 HTR2A (0.34) CRHR1HTR1AHTR2CHTR2BMEN1
SCHEMBL16201391 0.83 CHRM2 (0.45) HTR1AHTR2CHTR2BHTR7
SCHEMBL16201367 0.83 ALDH1A1 (0.35) CARM1HTR1AHTR2CHTR2BHTR7
SCHEMBL16201348 0.83 NISCH (0.36) CRHR1CARM1HTR1AHTR7PRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9776972-B2 Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof EPIZYME INC. (US) 2017-10-03 US disclosed
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-05-19 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 CRHR1 3768/4885CARM1 11/4885PRMT3 2/4885
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 CRHR1 3785/4885CARM1 12/4885PRMT3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.